Psyence Biomedical Ltd.
PBM
$1.77
$0.1912.03%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 28.86% | 4.79% | 46.76% | 46.76% | 382.13% |
| Depreciation & Amortization | 30.00% | 44.44% | 1,100.00% | 1,100.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.18% | 25.21% | 34.28% | 34.28% | 556.70% |
| Operating Income | -30.18% | -25.21% | -34.28% | -34.28% | -556.70% |
| Income Before Tax | -632.37% | -167.31% | 96.07% | 96.07% | 145.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -632.37% | -167.31% | 96.07% | 96.07% | 145.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -632.37% | -167.31% | 96.07% | 96.07% | 145.69% |
| EBIT | -30.18% | -25.21% | -34.28% | -34.28% | -556.70% |
| EBITDA | -30.17% | -25.19% | -34.09% | -34.11% | -- |
| EPS Basic | -112.48% | -101.84% | 99.75% | 99.75% | 129.47% |
| Normalized Basic EPS | 97.58% | 95.52% | 83.98% | 83.98% | -200.89% |
| EPS Diluted | -112.53% | -101.84% | 99.75% | 99.75% | 129.44% |
| Normalized Diluted EPS | 97.57% | 95.52% | 83.98% | 83.98% | -200.82% |
| Average Basic Shares Outstanding | 4,169.45% | 3,565.74% | 1,494.20% | 1,494.20% | 54.91% |
| Average Diluted Shares Outstanding | 4,169.45% | 3,553.10% | 1,494.20% | 1,494.20% | 54.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |